Hepatitis D epidemiology and demographics: Difference between revisions
No edit summary |
|||
| Line 6: | Line 6: | ||
===Prevalence=== | ===Prevalence=== | ||
Worldwide, | Worldwide, between 15-20 million people with chronic HBV infection are thought to have HDV co-infection or superinfection. With the implementation of HBV vaccination programs, better education and awareness about the virus, and improving socioeconomic conditions, HDV prevalence is decreasing in many areas of the world. | ||
===Developing countries=== | ===Developing countries=== | ||
| Line 20: | Line 20: | ||
===Developed Countries=== | ===Developed Countries=== | ||
HDV infection remains prevalent in France whereas in Germany and the UK, the prevalence has increased | HDV infection remains prevalent in France whereas in Germany and the UK, the prevalence has increased. In Italy, HDV prevalence was previously decreasing, and has now recently plateaued. These changes in prevalence are mainly attributable to the immigration of persons from regions of high endemicity.<ref name="pmid20051970">{{cite journal| author=Wedemeyer H, Manns MP| title=Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. | journal=Nat Rev Gastroenterol Hepatol | year= 2010 | volume= 7 | issue= 1 | pages= 31-40 | pmid=20051970 | doi=10.1038/nrgastro.2009.205 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20051970 }} </ref> | ||
== | |||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Hepatitis|D]] | [[Category:Hepatitis|D]] | ||
Revision as of 15:06, 8 August 2014
|
Hepatitis D |
|
Diagnosis |
|
Treatment |
|
Hepatitis D epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Hepatitis D epidemiology and demographics |
|
Risk calculators and risk factors for Hepatitis D epidemiology and demographics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Varun Kumar, M.B.B.S. [2]
Epidemiology and Demographics
Prevalence
Worldwide, between 15-20 million people with chronic HBV infection are thought to have HDV co-infection or superinfection. With the implementation of HBV vaccination programs, better education and awareness about the virus, and improving socioeconomic conditions, HDV prevalence is decreasing in many areas of the world.
Developing countries
Areas of high endemicity include Central Africa, the Horn of Africa, the Middle East, eastern and Mediterranean Europe, the Amazon Basin, and parts of Asia. HDV infection rates usually correlate with HBV endemicity except in countries such as Indonesia and Vietnam, where co-infection is uncommon. Prevalence of HDV infection ranges between provinces in China, a country with high endemicity of HBV. [1]
Two epidemiological patterns of hepatitis D infection exist: in Western Europe and North America, HDV is limited to persons exposed to blood or blood products such as with intravenous drug use. In Mediterranean countries, HDV infection is endemic among HBV carriers. In this population, the virus is transmitted by close personal contact. [2]
New foci of HDV superinfection continue to be identified in Mongolia, Greenland, Ecuador, and Venezuela.
HDV prevalence is decreasing in many areas of the world including Spain, Turkey, and Taiwan, especially in the last three decades. This has been attributed to vaccination programs for HBV, increased awareness, and an overall improvement in socioeconomic conditions. [1] It should be noted that data for HBV prevalence in developing countries is sparse.
Developed Countries
HDV infection remains prevalent in France whereas in Germany and the UK, the prevalence has increased. In Italy, HDV prevalence was previously decreasing, and has now recently plateaued. These changes in prevalence are mainly attributable to the immigration of persons from regions of high endemicity.[4]
- ↑ 1.0 1.1 Hughes SA, Wedemeyer H, Harrison PM (2011). "Hepatitis delta virus". Lancet. 378 (9785): 73–85. doi:10.1016/S0140-6736(10)61931-9. PMID 21511329.
- ↑ World Health Organization. Department of Communicable Disease Surveillance and Response.http://www.who.int/csr/disease/hepatitis/HepatitisD_whocdscsrncs2001_1.pdf?ua=1
- ↑ "Center for Disease Control and Prevention (CDC)".
- ↑ Wedemeyer H, Manns MP (2010). "Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead". Nat Rev Gastroenterol Hepatol. 7 (1): 31–40. doi:10.1038/nrgastro.2009.205. PMID 20051970.